Bristol Myers, Pfizer score another win in their Eliquis patent defense, protecting the blockbuster until 2028
As a top-selling drug worldwide, Pfizer and Bristol Myers Squibb’s Eliquis is a major target for generic players looking to steal branded sales. But with a new court ...
Continue Reading →
